127 related articles for article (PubMed ID: 31282240)
21. Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscape.
Schwind S; Jentzsch M; Kubasch AS; Metzeler KH; Platzbecker U
Neoplasia; 2021 Nov; 23(11):1101-1109. PubMed ID: 34601234
[TBL] [Abstract][Full Text] [Related]
22. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
23. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients.
Rossi G; Pelizzari AM; Bellotti D; Tonelli M; Barlati S
Leukemia; 2000 Apr; 14(4):636-41. PubMed ID: 10764149
[TBL] [Abstract][Full Text] [Related]
24. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
25. Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Neukirchen J; Lauseker M; Hildebrandt B; Nolting AC; Kaivers J; Kobbe G; Gattermann N; Haas R; Germing U
Cancer; 2017 Dec; 123(23):4608-4616. PubMed ID: 28746789
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
27. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
Bains A; Luthra R; Medeiros LJ; Zuo Z
Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.
Bally C; Adès L; Renneville A; Sebert M; Eclache V; Preudhomme C; Mozziconacci MJ; de The H; Lehmann-Che J; Fenaux P
Leuk Res; 2014 Jul; 38(7):751-5. PubMed ID: 24836762
[TBL] [Abstract][Full Text] [Related]
29. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome.
Hou HA; Tsai CH; Lin CC; Chou WC; Kuo YY; Liu CY; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Yao M; Tang JL; Tien HF
Blood Cancer J; 2018 Apr; 8(4):39. PubMed ID: 29618722
[TBL] [Abstract][Full Text] [Related]
31. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
[TBL] [Abstract][Full Text] [Related]
32. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression.
Hou HA; Kuo YY; Tang JL; Chou WC; Yao M; Lai YJ; Lin CC; Chen CY; Liu CY; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):181-6. PubMed ID: 24127063
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
35. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
36. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
[TBL] [Abstract][Full Text] [Related]
37. DICER1 gene and miRNA dysregulation in mesenchymal stem cells of patients with myelodysplastic syndrome and acute myeloblastic leukemia.
Ozdogan H; Gur Dedeoglu B; Oztemur Islakoglu Y; Aydos A; Kose S; Atalay A; Yegin ZA; Avcu F; Uckan Cetinkaya D; Ilhan O
Leuk Res; 2017 Dec; 63():62-71. PubMed ID: 29102598
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents.
Takahashi K; Patel K; Bueso-Ramos C; Zhang J; Gumbs C; Jabbour E; Kadia T; Andreff M; Konopleva M; DiNardo C; Daver N; Cortes J; Estrov Z; Futreal A; Kantarjian H; Garcia-Manero G
Oncotarget; 2016 Mar; 7(12):14172-87. PubMed ID: 26871476
[TBL] [Abstract][Full Text] [Related]
39. [Genomic aberrations in myelodysplastic syndromes and related disorders].
Makishima H
Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151
[TBL] [Abstract][Full Text] [Related]
40. Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
Mei C; Ren Y; Zhou X; Ye L; Ma L; Luo Y; Lin P; Xu W; Lu C; Yang H; Yu W; Mao L; Wei J; Jin J; Tong H
Leuk Lymphoma; 2019 May; 60(5):1136-1145. PubMed ID: 30301399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]